Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Hematology | Cardiology/Vascular Diseases | Family Medicine
Dyslipidemia Clinical Trials
A listing of Dyslipidemia medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Huntsville : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Mobile : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Arizona
Glendale : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Phoenix : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Tucson : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Tuscon : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
California
Banning : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Berkeley : Cholesterol Research Center, Children's Hospital Oakland Research Institute
Effects of High Fruit, Vegetable, and Dairy Intake on Plasma Lipids and Blood Pressure in Healthy Individuals
Escondido : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Harbor City : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Huntington Beach : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Laguna Hills : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Long Beach : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Los Alamitos : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Los Angeles : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Newport Beach : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Oceanside : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Oxnard : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Palm Springs : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Roseville : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Sacramento : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
San Diego : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Torrance : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Valley Village : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Westlake Village : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Colorado
Aurora : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Colorado Springs : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Denver : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Greeley : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Littleton : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Longmont : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Connecticut
Bridgeport : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Delaware
Seaford : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
District of Columbia
Washington : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Washington : Georgetown University
Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients
Florida
Bradenton : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Crystal River : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Daytona Beach : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Delray Beach : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Fleming Island : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Hollywood : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Jacksonville : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Jacksonville Beach : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Lakeland : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Melbourne : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Miami : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
New Port Richey : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
New Smyrna Beach : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Orlando : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Palm Harbor : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Pembroke Pines : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Pensacola : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Port Charlotte : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Saint Petsburg : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Sanford : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Sarasota : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
St. Petersburg : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Georgia
Athens : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Atlanta : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Dunwoody : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Gainesville : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Suwanee : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Idaho
Boise : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Coeur D'Alene : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Meridian : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Nampa : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Illinois
Addison : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Belleville : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Chicago : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Jerseyville : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Indiana
Hammond : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Indianapolis : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Valparaiso : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Iowa
Ames : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Waterloo : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Kansas
Hutchinson : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Overland Park : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Wichita : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Kentucky
Lexington : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Owensboro : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Louisiana
Baton Rouge : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Hammond : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Monroe : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Natchitoches : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Slidell : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Maine
Auburn : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Bangor : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Biddeford : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Portland : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Maryland
Baltimore : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Columbia : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Hollywood : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Salisbury : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Massachusetts
Hyannis : Clinical Research Center of Cape Cod, Inc
Do you have Hypercholesterolemia or Mixed Dyslipidemia?
View More »
Billerica : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Brockton : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Fall River : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Haverhill : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Hyannis : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Newton : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Watertown : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Michigan
Ann Arbor : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Dearborn : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Flint : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Grandville : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Novi : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Saginaw : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Traverse City : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Minnesota
Minneapolis : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Saint Paul : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
St. Cloud : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Mississippi
Olive Branch : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Tupelo : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Missouri
Jefferson City : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Kansas City : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
St Louis : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Montana
Billings : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Kalispell : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Nebraska
Lincoln : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Omaha : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Nevada
Las Vegas : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
New Jersey
Elizabeth : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Voorhees : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Westwood : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
New York
Manhasset : North Shore Long Island Jewish Division of Medical Genetics
Trial in Children With Growth Failure Due to Early Onset Lysosomal Acid Lipase (LAL) Deficiency/Wolman Disease
View More »
Brooklyn : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Cortlandt Manor : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Kingston : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
New Hyde Park : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
New York : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Rochester : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Troy : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
West Seneca : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Williamsville : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
North Carolina
Asheville : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Charlotte : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Greensboro : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Hickory : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
High Point : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Lenoir : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Mooresville : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Raleigh : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Statesville : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Wilmington : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
North Dakota
Fargo : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Grand Forks : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Ohio
Cincinnati : Medpace CPU
A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003
Cincinnati : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Columbus : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Dayton : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Elyria : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Garfield Heights : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Marion : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Sandusky : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Springfield : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Toledo : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Westlake : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Oklahoma
Oklahoma City : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Tulsa : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Oregon
Bend : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Portland : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Pennsylvania
Abington : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Altoona : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Camp Hill : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Chambersburg : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Feasterville : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Indiana : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Norristown : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Philadelphia : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Pittsburgh : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Uniontown : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
York : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Rhode Island
Cumberland : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Johnston : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Warwick : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
South Carolina
Anderson : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Columbia : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Mount Pleasant : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Mt. Pleasant : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Orangeburg : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Simpsonville : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Tennessee
Jackson : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Nashville : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Tullahoma : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Texas
Arlington : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Austin : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Dallas : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Houston : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Kerrville : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Longview : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Odessa : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Plano : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
San Antonio : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Sugar Land : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Tomball : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Utah
Salt Lake City : Optimum Clinical Research, Inc.
Are you currently taking medication for your cholesterol, but your LDL (bad cholesterol) is still too high? If so, you may be able to participate in this cutting edge study.
Salt Lake City : Optimum Clinical Research, Inc.
Those with diabetes know they are at a higher risk of having heart attacks , strokes, and other cardiovascular complications. This study is looking at the effects of a new diabetes medication on cardiovascular risks in patient at high risk of having another stroke or heart attack.
View More »
Layton : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
West Jordan : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Virginia
Burke : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Danville : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Falls Church : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Hopewell : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Richmond : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Roanoke : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Suffolk : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Washington
Federal Way : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Seattle : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Wisconsin
Green Bay : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Madison : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Marshfield : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Argentina
Buenos Aires : Helios Salud
Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen
Australia
Adelaide : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Ashford : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Box Hill : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Camperdown : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Concord : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Epping : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Footscray : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Geelong : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Heidelberg : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Herston : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Hobart : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Kogarah : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Liverpool : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Nedlands : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
South Brisbane : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
St Leonards : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Woden : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Woodville South : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Austria
Graz : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Innsbruck : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Linz : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Salzburg : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Wels : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Wien : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Belgium
Aalst : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Anderlecht, Brussels : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Brussels : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Bruxelles : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Gent : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Liège : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Liege : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Turnhout : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Canada
Brampton : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Cambridge : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Gatineau : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Granby : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Greenfield Park : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Hamilton : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Kelowna : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Lachine : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
London : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Montreal : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Montreal : McGill Cardiovascular Health Improvement Program
The Healthy Options Feasibility Study
New Westminster : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Newmarket : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Oshawa : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Peterborough : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Quebec : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Regina : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Scarborough : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
St. John’s : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
St. Johns : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
St-Charles-Borromee : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
St-Jérôme : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Strathroy : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Terrebonne : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Thunder Bay : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Toronto : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Westmout : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Chile
Santiago : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Temuco : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Czech Republic
Brno : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Ostrava-Poruba : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Pardubice : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Praha 3 : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Praha 4 : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Denmark
Aalborg : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Ballerup : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Esbjerg : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Glostrup : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
København : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
København S : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Odense : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Svendborg : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Vejle : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Viborg : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Estonia
Harjumaa : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Paide : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Tallinn : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Finland
Hämeenlinna : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Helsinki : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Jyväskylä : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Kuopio : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Oulo : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Oulu : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Tampere : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Turku : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
France
Paris : Hôpital Necker-Enfants Malades
Trial in Children With Growth Failure Due to Early Onset Lysosomal Acid Lipase (LAL) Deficiency/Wolman Disease
View More »
Besançon : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Brest Cedex 2 : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Chambray les Tours : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Créteil : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Metz Cedex : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Nantes Cedex 2 : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Orléans : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Paris : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Perpignan Cedex : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Pessac Cedex : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Saint Priest en Jarez : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Strasbourg : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Toulouse Cedex 9 : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Vandoeuvre les Nancy : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Greece
Alexandroupoli : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Athens : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Chalkida : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Heraklion : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Ioannina : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Larissa : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Piraeus : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Thessaloniki : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Hungary
Balatonfured : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Budapest : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Gyongyos : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Komarom : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Szekszard : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Szolnok : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Zalaegerszeg : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Iceland
Reykjavik : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Italy
Padova : Azienda Ospedaliera Universita di Padova Updated
Trial in Children With Growth Failure Due to Early Onset Lysosomal Acid Lipase (LAL) Deficiency/Wolman Disease
View More »
Bergamo : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Chieti : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Colleferro RM : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Cortona AR : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Firenze : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Milano : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Napoli : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Palermo : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Pavia : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Siena : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Korea, Republic of
Chung Ju : Chungbuk National University Hospital
Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia
Daejeon : Konyang University Hospital
Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia
Seoul : Seoul National University Hospital
Clinical Study for Patients With Hypertension Associated With Dyslipidemia
Seoul : Gangnam Severance Hospital
Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia
Seoul : Hallym University Medical Center
Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia
View More »
Seoul : Korea University Guro Hospital
Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia
Seoul : Seoul National University Hospital
Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia
Seoul : Severance Hospital
Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia
Seoul : Samsung Medical Center
Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia
Seoul : Asan Medical Center
Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia
Suwon : Ajou University Medical Center
Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia
Latvia
Daugavpils : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Kuldiga : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Liepaja : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Ogre : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Riga : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Lithuania
Kaunas : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Klaipeda : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Vilnius : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Mexico
Aguascalientes : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Culiacan : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Guadalajara : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Queretaro : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
San Luis Potosi : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Xalapa : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Netherlands
Amsterdam : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Deventer : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Ede : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Eindhoven : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Goes : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Helmond : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Hoorn : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Leiden : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Oss : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Rotterdam : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Tiel : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Venlo : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Norway
Bodø : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Oslo : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Poland
Bydgoszcz : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Gdynia : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Gizycko : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Jelenia Gora : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Katowice : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Kielce : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Krakow : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Lodz : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Lublin : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Nowa Sol : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Olsztyn : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Plock : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Poznan : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Pszczyna : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Skierniewice : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Starogard Gdanski : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Tarnow : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Torun : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Warszawa : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Wloclawek : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Wroclaw : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Portugal
Almada : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Amadora : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Carnaxide : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Coimbra : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Lisboa : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Russian Federation
Barnaul : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Kemerovo : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Moscow : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Novovisibirsk : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Pushkin : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Saint Peterburg : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Saint Petersburg : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Saint-Petersburg : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Saratov : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Tyumen : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Singapore
Singapore : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Slovakia
Bardejov : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Bratislava : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Kosice : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Martin : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Nitra : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Presov : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
South Africa
Amanzimtoti : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Bloemfontein : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Cape Town : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Cape Town : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Durban : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Kuils River : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Lyttelton : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Midrand : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Paarl : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Parow : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Somerset West : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Worcester : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Spain
Córdoba : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
San Juan de Alicante : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Santiago de Compostela : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Valencia : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Zaragoza : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Sweden
Ã-rebro : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Ã-stersund : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Bollnäs : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Eksjö : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Eskilstuna : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
View More »
Falun : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Helsingborg : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Jönköping : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Linköping : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Lund : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Stockholm : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Uddevalla : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Umeå : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Västerås : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Taiwan
Taipei : National Taiwan University Hospital
Trial in Children With Growth Failure Due to Early Onset Lysosomal Acid Lipase (LAL) Deficiency/Wolman Disease
United Kingdom
Pendlebury : Manchester Children's Hospital
Trial in Children With Growth Failure Due to Early Onset Lysosomal Acid Lipase (LAL) Deficiency/Wolman Disease
View More »
Birmingham : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Cardiff : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Chorley : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Liverpool : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Manchester : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Reading : Research Site
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
